Abel Hall LLC
IOVA icon

Abel Hall LLC’s Iovance Biotherapeutics IOVA Stock Holding History

Abel Hall LLC’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$411K Buy
27,729
+2,610
+10% +$18.7K 0.07% 283
2026
Q2 		$104K Buy
25,119
+713
+3% +$2.71K 0.02% 830
2026
Q1 		$85.7K Buy
+24,406
New +$78.1K 0.02% 704

Other funds holding IOVA

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Abel Hall LLC's IOVA Position: Q3 2026 in Review

Abel Hall LLC increased its Iovance Biotherapeutics (IOVA) stake by 10% in Q3 2026, buying an estimated $18.7K and bringing the position to 27,729 shares worth $411K. The position accounts for 0.07% of the portfolio, ranked #283.

Abel Hall LLC first reported a position in IOVA in Q1 2026 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

  • Abel Hall LLC held 27,729 shares of Iovance Biotherapeutics worth $411K as of Q3 2026.
  • Abel Hall LLC bought 2,610 Iovance Biotherapeutics shares in Q3 2026, an estimated $18.7K.
  • Iovance Biotherapeutics made up 0.07% of Abel Hall LLC's portfolio in Q3 2026, its #283 holding.
  • Abel Hall LLC first reported a position in Iovance Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • 109 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.